tion of the process. Such a report could identify the nature of errors and their impacts on the outcome of the study and could be used to make theories about the impacts of undetected errors. Although standardization and simplification are desirable goals, industry may be reluctant to be the test case for innovative approaches unless FDA approved such approaches by prior agreement.
The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Presubmission and Submission ."
Assuring Data Quality and Validity in Clinical Trials for Regulatory Decision Making: Workshop Report . Washington, DC: The National Academies Press,
Please select a format: